LGMN and neoplasm: Legumain (LGMN) is an asparaginyl-specific cysteine endopeptidase that has been identified as a hypoxia-responsive gene and the combined use of LGMN inhibitor and PD-1 inhibitor could enhance anti-tumor efficacy [39, 40].